Tarah J. Ballinger, MD, considers the plight of patients with triple-negative breast cancer, who frequently experience recurrence of their cancer as a consequence of residual disease.
But there is light on the horizon, Dr Ballinger counsels. New diagnostic and monitoring innovations such as circulating tumor DNA (ctDNA), which offer more prompt assessment of disease status, are poised to enter the early breast cancer space, permitting clinicians to assemble more targeted therapeutic strategies that will improve patient outcomes.
Medscape © 2022 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: Management of Early-Stage Breast Cancer: Reducing the Risk for Recurrence - Medscape - Aug 01, 2022.